Melanoma Clinical Trials

Showing 581-600 of 1,292 trials

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

NCT00053781

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have metastatic or recurrent malignant melanoma.

Melanoma (Skin)

NCIC Clinical Trials Group18 participantsStarted Jun 2003

Calgary, Alberta, Canada • Halifax, Nova Scotia, Canada • London, Ontario, Canada +3 more locations

COMPLETEDPhase 2

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

NCT00514085

RATIONALE: Interleukin-21 may stimulate white blood cells, including natural killer cells, to kill melanoma cells. PURPOSE: This phase II trial is studying the side effects and how well interleukin-21 works in treating patients with metastatic or recurrent malignant melanoma.

Melanoma (Skin)

NCIC Clinical Trials Group40 participantsStarted Dec 2007

Edmonton, Alberta, Canada • Surrey, British Columbia, Canada • Vancouver, British Columbia, Canada +4 more locations

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Related Searches

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

App Teaches Doctors to Diagnose Skin Cancer

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

'Cancer Patients Better Life Experience'

Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma

Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

Mobile Devices as Educational Skin History Tools

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

The MELAcare Study: A New Method for Surveillance of Melanoma Patients

Vascular Response to Brachytherapy Using Functional OCT

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)